Ph.D. (Biol.)
Post doctoral researcher
Dr. Maria Jäntti joined PREP lab on fall 2017. Her project is testing novel PREP ligands in different models of neurodegenerative diseases.
Education
M.Sc. (Biol.), University of Oulu, Finland, 2009
Ph.D. (Biol.), University of Helsinki, Finland, 2015
Publications
Virpi Talman, Alessia Pascale, Maria Jäntti, Marialaura Amadio, Raimo K. Tuominen Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer’s Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins? Basic Clin Pharmacol Toxicol, 119: 149-60, 2015
Louhivuori LM, Jansson L, Turunen PM, Jäntti MH, Nordström T, Louhivuori V, Åkerman KE. Transient receptor potential channels and their role in modulating radial glial-neuronal interaction: a signaling pathway involving mGluR5. Stem Cells Dev. 24:701-13, 2015.
Jäntti MH, Mandrika I, Kukkonen JP. Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun. 445:486-90, 2014
Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. Mol Pharmacol. 83:621-32, 2013
Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release. Mol Pharmacol. 82:156-67, 2012
Jäntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP. OX1 orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol. 165: 1109-23, 2012
Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP. Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett. 494: 57-60. 2011